Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: In inflammatory skin disease, hydrocortisone and prednisolone double esters are about equipotent to conventional medium potency topical glucocorticoids, such as betamethasone valerate. Local adverse effects, in particular skin atrophy, are a potential problem with topical glucocorticoids. Recently, cell cultures have shown promise as a means of assessing local tolerance.To investigate the toxic potential of hydrocortisone, hydrocortisone-17-butyrate, hydrocortisone aceponate, prednicarbate, triamcinolone acetonide, betamethasone valerate and desoximethasone, human keratinocytes and fibroblasts were exposed to these agents in vitro, using a modified neutral red release assay. In addition, the morphology of these cells was assessed by light microscopy.Although all the topical glucocorticoids tested proved toxic to both cell types, there were major differences between glucocorticoids in their effect on fibroblasts. Hydrocortisone and the nonhalogenated double-ester-type glucocorticoids were less toxic than the conventional medium potency topical glucocorticoids tested (betamethasone valerate and desoximethasone). In particular, hydrocortisone aceponate was less toxic than betamethasone valerate (P 〈inlineGraphic alt="leqslant R: less-than-or-eq, slant" extraInfo="nonStandardEntity" href="urn:x-wiley:00070963:BJD54:les" location="les.gif"/〉 0.05). In general, the effect of topical glucocorticoids on the cells, based on neutral red release, was more marked with keratinocytes than with fibroblasts. Although the ranking order with respect to the toxic potential was similar, a clear-cut difference was not observed between non-halogen a ted double-ester-type glucocorticoids and betamethasone valerate. Morphological changes due to glucocorticoid exposure followed the same pattern with both keratinocytes and fibroblasts.The neutral red release assay is able to discriminate between the cytotoxic effects of chemically differing topical glucocorticoids on human keratinocytes and fibroblasts. The present data support the hypothesis of an increase in benefit/risk ratio with the new double esters of hydrocortisone and prednisolone.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1912
    Keywords: UD-CG 115 ; Pyridazinone ; Phosphodiesterase inhibitor ; Positive inotropic effect ; Cyclic AMP ; Cardiac action potential
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary 1. The mechanism of the positive inotropic effect of a benzimidazole-pyridazinone, UD-CG 115, was analysed in the isolated guinea-pig papillary muscle contracting isometrically at a frequency of 0.2 Hz. 2. UD-CG 115 produced a slowly developing and poorly reversible positive inotropic effect increasing with concentration (3–300 μmol/l). The effect amounted to 30 and 74% of the maximum inotropic effect of a standard, dihydroouabain, at 34 and 300 μmol/l, respectively. Low concentrations shortened and 300 μmol/l UD-CG 115 significantly prolonged the duration of contraction. The enhancement of the maximum rate of relaxation, S 2, was intermediate between those produced by isoprenaline and dihydroouabain, respectively. 3. UD-CG 115 prolonged the duration of the transmembrane action potential (90% repol.) by up to 22% at 300 μmol/l, whereas an equieffective concentration of isoprenaline did not consistently alter action potential duration. UD-CG 115 increased V max and overshoot, and prolonged the duration, of slow action potentials elicited at 24 mmol/l [K]0. 4. The inotropic potency of UD-CG 115 was not significantly changed by reserpine pretreatment of the guinea pig or by the presence of 1 μmol/l (−)-propranolol, 3 μmol/l phentolamine or 10 μmol/l cimetidine. Neither was it reduced by 10 μmol/l TTX. The inotropic effect of 100 μmol/l UD-CG 115 remained unchanged when [K]0 was elevated from 3.2 to 12.0 mmol/l. A sarcolemmal preparation of guinea-pig ventricular Na,K-ATPase was only slightly inhibited by the highest concentration of UD-CG 115. 5. Carbachol (0.1–3 μmol/l) inhibited the positive inotropic effect of UD-CG 115, and this antagonism disappeared in the presence of 1 μmol/l atropine. 6. In the presence of a moderately effective concentration of UD-CG 115 (10 μmol/l) the inotropic potencies (-log EC50) of isoprenaline, histamine, and IBMX were all significantly increased by 0.60±0.07, 0.36±0.06, and 0.44±0.06 log units, respectively, whereas that of dihydroouabain was not significantly affected. 7. UD-CG 115 increased the force of the rested-state contraction by augmenting the late component of contraction. 8. Cyclic AMP content determined by radioimmunoassay in individual papillary muscles was raised 1.64-fold in the presence of 10 μmol/l UD-CG 115, but did not significantly increase beyond this level when drug concentration was raised further up to 30-fold. Carbachol prevented the effect of UD-CG 115 on cyclic AMP content. 9. Addition of UD-CG 115 in the presence of the maximally effective concentration of isoprenaline gave a further positive inotropic and klinotropic effect, whereas the phosphodiesterase inhibitor IBMX was without effect on contraction under this condition. 10. These findings are consistent with the proposal that the inotropic action of UD-CG 115 depends on a moderate elevation of cyclic AMP (not involving β-adrenoceptors or histamine-H2-receptors but probably due to phosphodiesterase inhibition) combined with a prolongation of the action potential that augments the inotropic cyclic AMP effect by increasing Ca influx through Ca channels.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Naunyn-Schmiedeberg's archives of pharmacology 318 (1981), S. 112-120 
    ISSN: 1432-1912
    Keywords: Amrinone ; Positive inotropic effect ; Cardiac cyclic AMP ; Phosphodiesterase inhibitor ; Slow inward current
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Using the isolated guinea-pig papillary muscle and conventional methods for recording isometric force and transmembrane electrical activity we analysed the positive inotropic effect of the bipyridine derivative amrinone at a contraction frequency of 0.2 Hz. The drug produced a concentration-dependent (0.06–8.0 mmol/l), reversible increase in force of contraction associated with an abbreviation of relaxation time at low concentrations and an increase of this parameter at high concentrations. Part of the inotropic effect was manifested by the rested-state contraction. In muscles depolarized by 24 mmol/l [K]0, amrinone increased the maximum rate of depolarization and overshoot of the slow responses. Carbachol reduced the inotropic effect of amrinone, and this antagonism was removed by the additional application of atropine. The inotropic effect of amrinone was not affected by propranolol or phentolamine and only slightly inhibited by cimetidine. Amrinone potentiated the positive inotropic effects of isoprenaline or histamine but interacted additively with dihydroouabain; the −log EC50 of isoprenaline was increased by 0.803±0.077 and that of histamine by 1.14±0.054 logarithmic units in the presence of 0.2 mmol/l amrinone. Abbreviation of relaxation time, increase in force of the rested-state contraction, atropine-sensitive antagonism by carbachol, and the effects on the slow response are characteristic of the class of cardiotonic drugs thought to act by increasing the cellular concentration of cyclic AMP. Direct support for this hypothesis was provided by the demonstration that inotropically effective concentrations of amrinone produced an up to 3.5-fold increase in cyclic AMP content of guinea-pig papillary muscles. In addition, amrinone was found to inhibit phosphodiesterase in a crude enzyme preparation from guinea-pig ventricular strips. Lack of specific antagonism by propranolol or cimetidine and potentiation of the effects of isoprenaline or histamine are consistent with an inhibitory effect on cyclic nucleotide phosphodiesterase. At high concentrations, amrinone was shown to exert an additional theophylline-like effect on the contour of the isometric contraction that cannot be attributed to cyclic AMP accumulation.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Naunyn-Schmiedeberg's archives of pharmacology 335 (1987), S. 166-175 
    ISSN: 1432-1912
    Keywords: 8-Substituted cyclic AMP ; Positive inotropic effect ; Phosphodiesterase inhibition ; Carbachol ; Cellular cyclic AMP
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The influence of phosphodiesterase inhibitors and of carbachol on the positive inotropic effect of 8-substituted cyclic AMP analogues was studied on isometrically contracting guinea-pig papillary muscles driven at a rate of 0.2 Hz. 1. In muscles from reserpine-pretreated animals, the phosphodiesterase inhibitors 3-isobutyl, 1-methyl xanthine (IBMX; 20 μmol/l) and papaverine (10 gmol/1) shifted the concentration-effect curves of 8-substituted cyclic AMP benzyl esters to the left, decreasing the EC50 by a factor of 10 to 25. 2. In the presence of IBMX (5 and 20 gmol/1) or papaverine (10 gmol/1), the slopes of the concentration-effect curves of 8-substituted cyclic AMP benzyl esters became flatter. 3. The positive inotropic effect and the increase in V max, overshoot and duration of slow action potentials induced by cyclic AMP analogues were not affected by carbachol (0.1–10 μmol/l). In the presence of IBMX (20 μmol/l), however, carbachol (3 gmol/1) antagonized the positive inotropic effect of 8-substituted cyclic AMP derivatives, shifting the EC50-values by a factor of 3 to the right. 4. Cyclic AMP content determined by radioimmunoassay in individual papillary muscles was raised 1.22 and 1.63-fold in the presence of 3 and 20 μmol/l IBMX. Isoprenaline (0.1 μmol/l) induced an increase in cyclic AMP content which was not significantly different from that produced by 20 μmol/l IBMX, but in contrast to the phosphodiesterase inhibitor enhanced force of contraction by 17.7 mN as compared to 1.5 mN obtained with 20 μmol/l IBMX. 5. The findings are consistent with a model that describes the interaction between IBMX and cyclic AMP analogues as an additive effect with only endogenously accumulated cyclic AMP (due to phosphodiesterase inhibition) being involved in the negative inotropic effect of carbachol. From the failure of carbachol to affect the positive inotropic effect of cyclic AMP analogues, it is concluded, that cyclic AMP derivatives do not act as phosphodiesterase inhibitors, and that the well-known negative inotropic effect of carbachol in the presence of cyclic AMP-elevating drugs does not occur at a step beyond cyclic AMP accumulation.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Archives of dermatological research 272 (1981), S. 1-7 
    ISSN: 1432-069X
    Keywords: 8-MOP ; Plasma level ; Intraindividual variations ; 8-MOP-Plasmaspiegel ; intraindividuelle Schwankungen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Intraindividuelle Schwankungen der 8-Methoxypsoralen-(8-MOP)-Plasmaspiegel wurden untersucht. 8-MOP-Plasmaspiegel wurden 2 h nach oraler Gabe von 0,56–0,82 mg/kg Körpergewicht an mindestens 3 aufeinander folgenden Behandlungstagen bestimmt. Am 1. Untersuchungstag wurde ein vollständiger Plasmaspiegel-Zeit-Verlauf gemessen. Die interindividuellen Schwankungen der 8-MOP-Plasmaspiegel betrugen 0–654 ng/ml. Die intraindividuellen Schwankungen waren wesentlich geringer (1,2–5,3fach). Bei einem Patienten, der eine niedrigere Resorptionsgeschwindigkeit für 8-MOP aufwies, schwankten die Plasmaspiegel zwischen 0 und 126 ng/ml. Die intraindividuellen Schwankungen (bestimmt als Quotient aus höchstem zu niedrigstem Plasmaspiegel) waren relativ eng mit dem Plasmaspiegelmittelwert korreliert (r=0,81). Die intraindividuellen Schwankungen nehmen mit ansteigendem 8-MOP-Plasmaspiegel exponentiell ab. Die Schwankungen der 8-MOP-Plasmaspiegel werden durch die intrinsische hepatische Clearance, die Leberdurchblutung und möglicherweise auch durch unterschiede in der Resorption aus dem Gastrointestinaltrakt bestimmt. Um die intraindividuellen Schwankungen der 8-MOP-Plasmaspiegel möglichst niedrig zu halten, wird empfohlen, das Arzneimittel zusammen mit einer standardisierten Mahlzeit zu verabreichen. Ferner sollte die Gabe von Pharmaka, die mit der Metabolisierung in der Leber oder mit der Leberdurchblutung interferieren, möglichst vermieden werden.
    Notes: Summary Intraindividual variations of 8-methoxypsoralen (8-MOP) plasma levels were investigated. On at least 3 consecutive days of treatment 8-MOP levels were determined 2 h following the administration of 0.56–0.82 mg/kg b.w. On day 1 a complete plasma level-time profile was obtained. Interindividually, 8-MOP plasma levels varied from 0–654 ng/ml. Intraindividual variation was considerably less being 1.2–5.3-fold. In one patient who showed a lower absorption rate of 8-MOP plasma levels varied from 0–126 ng/ml. There was a rather close correlation (r=0.81) of the variation of 8-MOP plasma levels (determined as the ratio of highest to lowest plasma level) and mean plasma level, intraindividual variation decreasing exponentially with increasing 8-MOP plasma levels. Parameters determining variation of 8-MOP plasma levels are the intrinsic hepatic clearance, liver blood flow, and possibly the absorption of the drug from gastrointestinal tract. To keep intraindividual variation as low as possible ingestion of the drug together with a standardized meal is suggested. Drugs interfering with hepatic metabolism or liver blood flow should be avoided.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 23 (1982), S. 327-330 
    ISSN: 1432-1041
    Keywords: bendroflumethiazide ; cantharides plasters ; blister fluid ; plasma levels ; pharmacokinetics ; compartmental analysis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The pharmacokinetics of bendroflumethiazide (BFT) was investigated following the oral administration of 10 mg to 3 healthy volunteers. Each subject participated twice in the study. BFT was determined in plasma and cantharides blister fluid from 1/2 to 30 h post administration. Blister fluid was obtained from blisters 10–22 h old. Plasma levels were fitted to a tri-exponential equation and the concentration of the drug in the peripheral compartment was calculated from the microscopic rate constants. In 5 of 6 cases investigated, cantharides blister fluid levels paralleled the concentration of the drug in the peripheral compartment. The mean blister fluid levels exceeded the calculated concentration in Compartment 2 1.46 fold. In one case, the blister fluid level paralleled the plasma level. This subject clearly differed from the others as more than 10 h were required for blister formation in her. The results suggest that following the administration of BFT, cantharides blister fluid behaves as part of the peripheral compartment. The possible value of studying blister fluid levels in pharmacokinetic investigations is discussed.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 26 (1984), S. 125-127 
    ISSN: 1432-1041
    Keywords: nadolol ; pharmacokinetics ; plasma levels ; urinary excretion ; bioavailability ; circadian rhythm
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary In 7 healthy subjects (3 males and 4 females), the kinetics of nadolol was investigated after oral doses of 60 and 120 mg. The t1/2 was 14.0±1.8 h. The peak plasma level was doubled on doubling the dose (from 69±15 to 132±27 ng/ml, respectively) and the urinary excretion (13.5%) rose similarly. The half-life of elimination was longer at night than in the day, probably because of the slower nocturnal flow of urine.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-1041
    Keywords: beta-blockers ; radioreceptor assay ; propranolol ; carteolol ; active metabolites ; rat reticulocyte membranes ; CGP 12177
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary A radioreceptor assay (RRA) for the assay of beta-adrenoceptor antagonists in native human plasma is described. The hydrophilic antagonist3H-CGP 12177 was used as the radioligand. In contrast to the hydrophobic radioligand3H-dihydroalprenolol, which was investigated in parallel, the beta-adrenoceptor binding of3H-CGP 12177 by rat reticulocyte membranes was found not to be affected by inclusion of increasing proportions (0–66% of incubation volume) of human plasma in the assay. Thus, solvent extraction of drug and/or active metabolites was not necessary to avoid binding of the radioligand tracer to plasma added in the RRA. The assay of unprocessed samples was possible. Drug concentrations in plasma after oral administration of propranolol (240 mg) or carteolol (30 mg) to 6 healthy volunteers were measured by the RRA and in parallel by a chemical method. The results from both methods agreed when the plasma concentration kinetics of propranolol were investigated (elimination half-life: 3.9 h). In contrast, plasma concentrations of carteolol were consistently higher according to the RRA after oral administration of the drug. Identical concentrations, however, were found by the RRA and chemical method using plasma samples spiked with carteolol. Plasma concentrations of carteolol detected by the chemical method decline monoexponentially (elimination half-life: 5.4 h). A similar half-life of elimination for parent drug was found by the RRA (5.9 h), but an additional term describing the appearance of an active metabolite was necessary to account for the biphasic drug elimination (elimination half-life of metabolite: 17.3 h). The latter result is in agreement with the appearance of 8-hydroxy-carteolol as an active metabolite, which shows similar affinity for beta-adrenoceptors as the parent drug. The active metabolite, with a 3-fold longer elimination half-life than the parent drug, will prolong the duration of the clinical effects of orally administered carteolol. In conclusion, the RRA permits the determination of beta-adrenoceptor antagonistic activity in native human plasma at concentrations as low as 0.1-fold the IC50-value of the drug or an active metabolite.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 29 (1985), S. 109-113 
    ISSN: 1432-1041
    Keywords: griseofulvin ; skin blister fluid levels ; pharmacokinetics ; healthy subjects ; bioavailability ; protein binding
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Griseofulvin and 6-demethylgriseofulvin (6-DMG) in plasma, suction blister fluid (SBF) and cantharides blister fluid (CBF) and urinary excretion of 6-DMG, were evaluated following administration of single oral doses of an ultramicrosize and a microsize formulation of griseofulvin to 6 healthy volunteers. The bioavailability of griseofulvin was higher following the ultramicrosize formulation when 64% of the dose was recovered (via metabolites) versus 52% after the microsize preparation. Penetration into skin blister fluid was delayed as compared to plasma levels; the peak concentration in plasma was observed at 3–4 h, whereas griseofulvin in CBF increased up to 6 h. The terminal half-live was calculated from plasma levels to 9.3 h. The half-lives calculated from SBF and CBF concentrations were 9.2 and 9.8 h, respectively, (n=5). In plasma 84% of griseofulvin was bound to proteins, predominantly to albumin; binding in SBF and CBF was 72 and 82%, respectively. 3 h after drug administration the free concentration in plasma significantly exceeded the free concentrations in SBF and CBF. Distribution equilibrium between plasma and skin blister fluid was observed after 27 h. Thus, during chronic administration, the plasma griseofulvin level should reflect its concentration in the target organ.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 29 (1985), S. 351-354 
    ISSN: 1432-1041
    Keywords: griseofulvin ; skin blister fluid ; plasma concentration ; blister fluid concentration ; pharmacokinetics ; microsize formulation ; urinary excretion ; bioavailability ; different formulations
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Griseofulvin was administered orally to 6 healthy volunteers for 6 days. The subjects received 500 mg of a microsize formulation and 330 mg of an ultramicrosize formulation, according to a cross-over design. The drug was determined in plasma, suction blister fluid (SBF) and cantharides blister fluid (CBF) following the last dose. Urinary excretion of the main metabolites 6-demethylgriseofulvin (6-DMG) and its glucuronic acid conjugate was also measured. The pharmacokinetic parameters were compared with those obtained from a recent single dose experiment. On repeated administration, the bioavailability of griseofulvin was significantly lower from the microsize formulation; the urinary recovery of total 6-DMG was 33.8% versus 53.6% on administration of the ultramicrosize material. Bioavailability was reduced as compared to ingestion of a single dose. The reduction was more prominent following the microsize (36%) than the ultramicrosize (17%) formulation. Penetration into skin blister fluid was not altered as compared to the single dose experiment. Relative areas under the blister fluid-time curves amounted to 51% (SBF) and 80% (CBF) of the area under the plasma level-time curve. The concentration of unbound griseofulvin in these body fluids was identical throughout the entire dosage interval. Unbound griseofulvin levels were low in comparison with the minimum inhibitory concentrations for strains of trichophyton and microsporum.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...